Cladribine (Mavenclad)
Cladribine (Mavenclad) is an oral medication for the treatment of relapsing forms of MS to include relapsing-remitting MS and active secondary progressive MS. Cladribine is administered orally at a weight based yearly treatment course for a total of two treatment courses. Each course has two dosing cycles separated by about a month. Cladribine is targeted, sustained reduction of T and B lymphocytes by inhibition of key enzymes involved in DNA and RNA synthesis and repair. In targeted cells, this leads to disruption of DNA repair and synthesis of new DNA, cell-cycle arrest, and apoptosis. Because of its safety profile, the use of cladribine should generally be reserved for people who have had an inadequate response to two or more drugs indicated for the treatment of MS.
Additional Information
- National MS Society Mavenclad
- VA Cladribine (Mavenclad) Drug Monograph (VA access only)
Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.
